NCI Cancer Center Support Grant (P30 Clinical Trial Not Allowed)

NCI Cancer Center Support Grant (P30 Clinical Trial Not Allowed) is sponsored by NIH NCI. Provides funding to support the infrastructure and shared resources of cancer centers to enhance their research capabilities.

Expired PAR-21-321: Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) This notice has expired. For NIH, in limited situations, applications may be accepted on a case-by-case basis for a short period after expiration to accommodate NIH late or continuous submission policies . Contact the eRA Service Desk for any submission issues.

Check the NIH Guide for active opportunities and notices. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) of Participating Organizations National Cancer Institute ( NCI )) Funding Opportunity Title Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional April 2, 2025 - This funding opportunity was updated to align with agency priorities. A Plan to Enhance Diversity (PED) core is no longer required.

Applications that contain the PED core will not be reviewed. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission. January 10, 2025 - Request for Information (RFI): Seeking Input on the Community Outreach and Engagement Component of the Cancer Center Support Grant (P30).

See Notice NOT-CA-25-031 April 04, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084 August 12, 2024 - Notice to Extend Expiration Date for PAR-21-321, Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional). See Notice NOT-CA-24-090 .

NOT-OD-23-012 Reminder: FORMS-H Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2023 - New Grant Application Instructions Now Available NOT-OD-22-190 - Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022 October 28, 2021 - Reminder: FORMS-G Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2022 - New Grant Application Instructions Now Available.

See Notice NOT-OD-22-018 . September 13, 2021 - Updates to the Non-Discrimination Legal Requirements for NIH Recipients. See Notice August 5, 2021 - New NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022.

August 5, 2021 - Update: Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements. See Notice NOT-OD-21-170 April 20, 2021 - Expanding Requirement for eRA Commons IDs to All Senior/Key Personnel. See Notice NOT-OD-21-109 Funding Opportunity Announcement (FOA) Number Companion Funding Opportunity Additional Information on Eligibility .

Assistance Listing Number(s) Funding Opportunity Purpose This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers.

CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research.

The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries.

Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the Open Date (Earliest Submission Date) Letter of Intent Due Date(s) The first standard due date for this FOA is January 25, All applications are due by 5:00 PM local time of applicant organization.

All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due dates. AIDS Application Due Date(s) New Date January 08, 2026 per issuance of NOT-CA-24-090 .

(Original Expiration Date: January 08, 2025 ) It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide , except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced.

Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV . When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information Part 2. Full Text of the Announcement I.

Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV.

Application and Submission Section V. Application Review Information Section VI. Award Administration Information Section VII.

Agency Contacts Section VIII. Other Information Full Text of Announcement Section I. Funding Opportunity This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers.

NCI-designated Cancer Centers serve as major sources of discovery into the nature of cancer and of the development of more effective approaches to prevention, diagnosis, and therapy. They contribute significantly to the development of Shared Resources that support cancer relevant research and they collaborate and coordinate their research efforts with other NCI-funded programs and investigators.

The objectives of the NCI Cancer Centers Program are to foster highly interactive cancer research through support of the Formal, interactive scientific Research Programs comprised of investigators with common scientific interests and goals, yielding competitively funded research grants and contracts and productive Centralized Shared Resources that provide access to technologies, services, and scientific consultation that enhance scientific interaction and Developmental Funding that allows the Center to pursue newly identified priorities, strengthen weaker scientific areas, and explore new Activities that engage the populations within the catchment area in the conducted research and other Center activities; Efforts to coordinate and enhance existing cancer research education, training, and career development activities; Centralized Cancer Center Administration for resources and services, fiscal management and other supportive activities, and Centralized scientific oversight of cancer clinical trials.

NCI support to Cancer Centers is intended to foster excellence in research across a broad spectrum of scientific and medical concerns relevant to cancer. To facilitate discovery and its translation into direct benefit to patients and the general public, the NCI awards CCSGs to institutions that have a critical mass of cancer-relevant scientific research.

The CCSG focus on research derives from the belief that a culture of discovery, scientific excellence, transdisciplinary research, and collaboration yields tangible benefits extending far beyond the generation of new knowledge. The National Cancer Act officially established the Cancer Centers Program in 1971.

The legislation was based on the report of a congressional committee, which concluded that a formalized Cancer Centers Program would provide a unity of purpose, a centralized platform for sharing concepts and resources, and a management structure necessary to achieve progress toward the goal of preventing and curing cancer.

The Act grandfathered in twelve existing Centers that were already receiving support through a variety of NCI grants and contracts and authorized the establishment of additional Centers. It also implemented a standard funding mechanism (the P30 Cancer Center Support Grant or CCSG) and guidelines, and created an administrative and organizational home for the Program at the NCI.

Based on this early legislation, qualified applicant institutions receive the CCSG award and accompanying NCI designation for successfully meeting a spectrum of rigorous competitive standards associated with scientific and organizational merit. While CCSG requirements have evolved over the years, the grant continues to support research infrastructure that enhances collaborative, transdisciplinary research productivity.

CCSG grants provide funding for formalized cancer Research Programs, Shared Resources, scientific and administrative management, planning and evaluation activities, development of new scientific opportunities, community outreach and engagement, coordination of cancer training and education, and centralized clinical trial Although the CCSG does not directly fund the wider range of activities at Cancer Centers, an NCI-designated Cancer Center links state-of-the-art research and care, thus perpetuating the translational continuum.

To decrease cancer incidence and mortality among populations within its catchment area, including underserved populations, it also establishes partnerships with other health delivery systems and state and community agencies for dissemination of evidence-based Over the past several decades, the number of NCI-designated Cancer Centers has grown extensively; today they are in a variety of organizational settings across the United States.

An NCI-designated Cancer Center is a local, regional, and national resource, directly serving its community and, through the knowledge it creates, the The NCI recognizes three types of Cancer Cancer Centers have scientific agendas primarily focused on basic laboratory research.

While not all basic findings require a translational endpoint, basic cancer centers conduct pre-clinical translation and develop linkages with other institutions that will foster application of laboratory findings for public benefit where appropriate. Cancer Centers have scientific agendas focused on basic laboratory; clinical; and prevention, cancer control, and population-based science. All areas of science are linked collaboratively.

Cancer Centers demonstrate reasonable depth and breadth of cancer research activities in each of three major areas: basic laboratory; clinical; and prevention, control, population-based science, as demonstrated in the formal Research Programs.

Comprehensive Cancer Centers also have substantial transdisciplinary research that bridges these scientific areas, which is evaluated in the Research Programs and as part of the Six Essential Characteristics (i.e. Transdisciplinary Collaboration and Coordination; see below).

They are effective in serving their catchment area, as well as the broader population, through the cancer research they support and the cancer control activities they undertake, as demonstrated in Community Outreach and Engagement.

They integrate cancer training and education of biomedical researchers and community health care professionals into programmatic efforts to enhance the scientific mission and potential of the Center, as demonstrated by the Cancer Research Training and Education Coordination component.

Comprehensive Centers are expected to be strong in all four areas indicated above; strengths in some areas cannot mitigate weaknesses in one or more other areas. NOTE: Clinical and Comprehensive Cancer Centers serve a specific catchment area , and in addition to cancer research of broad applicability, they conduct research of particular relevance to their catchment area.

A Center’s catchment area is the self-defined geographic area that the Center serves or intends to serve in the research it conducts, the communities it engages, and the outreach it performs. It must include the area from which the Center draws the majority of its patients, but may extend beyond that, and it must include the local area surrounding the Cancer Center.

It must be population-based, e.g., using census tracts, zip codes, county or state lines, or other geographically-defined boundaries. The Six Essential Characteristics of an NCI-designated A successful NCI-designated Cancer Center demonstrates strength in six essential characteristics.

Together, these characteristics maximize its scientific potential and produce a whole that is greater than the sum Space: Physical facilities dedicated to the conduct of cancer focused research, and to the Center’s Shared Resources, and administration, are appropriate and adequate for the task.

Capabilities: The Center takes maximum advantage of institutional capabilities in cancer research, engaging in appropriate planning and evaluation of Center strategies and activities.

If a consortium is proposed, the consortium institution(s) add significant cancer research expertise Collaboration and Coordination: Substantial coordination, interaction, and collaboration, both among Center members from a variety of disciplines and between Center members and investigators in other institutions, enhance and add value to the productivity and quality of research.

As appropriate to the nature of the research, Centers facilitate transition of scientific findings through the translational continuum, via coordination of research across NCI and other funding mechanisms and through collaborations Focus: The structure and objectives of the Center's Research Programs and other components, as well as, the Center members' grants, demonstrate a clearly defined cancer research focus.

Commitment: The Center is a formal organizational component of the institution, with sufficient space, positions, and discretionary resources to ensure its stability and fulfill the Center’s objectives. The Center Director has authorities appropriate for managing the Center and furthering its scientific mission.

The institution recognizes team science in its promotion Director: The Director is a highly qualified scientist and administrator with leadership experience and expertise appropriate for establishing a vision for the Center, advancing scientific goals, and managing a complex organization.

She or he is effective in using institutionally designated authorities to Major Research Areas of Cancer Centers and Types of Interactions An NCI-designated Cancer Center should feature vigorous interactions across its research areas, facilitating collaboration between basic laboratory; clinical; and prevention, control and population-based science investigators and the formal Research Programs of which they are a part.

The organizational approach should serve the science of the institution, with reasonable breadth and depth of cancer-focused scientific faculty and dedicated research facilities.

In addition, Centers should ensure that they are both fostering basic discovery and, as applicable, facilitating transition of scientific findings through the translational pipeline (i.e., basic to pre-clinical and early clinical development, then to Phase III trials or other types of definitive studies appropriate to the nature of the research).

Discoveries may be advanced through NCI and other peer-reviewed translational science and clinical trial funding mechanisms (e.g. grants for SPOREs, program projects, consortia for Phase 0/I/II Cancer Prevention Clinical Trials Program, and the NCI National Clinical Trials Network or NCTN) and other collaborative strategies, including external partnerships.

All Centers are encouraged to establish collaborative links that maximize productivity and result in appropriate application of findings.

The form and extent of these activities may vary, based on the type Depending on Center type, the major research areas may include the following: Research: Centers use their base of support to promote breadth and depth in basic laboratory research and transdisciplinary collaborations among investigators in basic discovery and other research areas, both within the Center and with other external partners.

Research: Cancer Centers engage in a broad spectrum of clinical studies with a variety of forms of sponsorship. A Cancer Center is a major source of innovative investigator-initiated clinical studies that can be exported to NCI s NCTN or other appropriate externally peer-reviewed funded mechanisms. Clinical studies involve relevant laboratory research whenever possible.

Cancer Centers foster translation between the laboratory and clinic and conduct early proof-of-principle clinical trials and lead, and/or participate in, NCI’s NCTN. Cancer Centers also participate in trials initiated by industry and other NCI-designated Cancer Centers and other external partners.

Control, and Population Science Research: While Cancer Centers may not be able to conduct research in all aspects of prevention, cancer control, and population science, and no one area is required, they demonstrate depth in grant support across several thematic areas (e.g., epidemiology, primary prevention, early detection, health services, dissemination, palliation, and survivorship).

They also demonstrate appropriate collaborative links to other research areas within the Center and with other NCI-designated Cancer Centers and other external partners. NCI supports the affiliation of independent scientific institutions with distinct scientific expertise with NCI-designated cancer centers to contribute to the development and actualization of the cancer center s research agenda.

This formalized relationship strengthens the science of the Center and further extends the benefits of its cancer research. Once approved by NCI following peer-review, a consortium partner becomes a formal part of the Cancer Center and may describe themselves as a part of the X NCI-designated cancer center. They may not display the NCI Cancer Center identity badges independently nor describe themselves as NCI-designated.

Only renewal (Type 2) applications may propose consortium arrangements, which must be fully functioning at the time of application; Type 1 applications may not propose consortium arrangements. A consortium partner with clinical activities must: Hold at least $2.

5 million in direct cost NIH-funded research project grants that are classified as cancer research by NIH’s Research, Condition, and Disease Categorization (RCDC), held by a minimum of 10 PD/PIs.

These grants cannot be counted as part of the Center until the consortium arrangement is approved by NCI, following acceptance of the arrangement by the NCI’s Cancer Centers Study Section (A) as part of their overall review of the P30 CCSG Contribute continuing tangible commitments to the Center.

These may include direct financial support of cancer research; discretionary funds placed at the Center Director’s disposal; protected cancer research time to support programmatic goals; leadership positions in the Center’s Research Programs or other components; efforts that expand the Center’s catchment area and activities of the Center’s Community Outreach and Engagement; common strategic planning and priorities (recruitment, clinical trials, grants, etc.); physical space for cancer research, etc. Be fully integrated at the level of membership and institutional engagement into the Cancer Center at the time of the CCSG application, as evidenced by a history of collaboration, including joint grants and publications, and mechanisms for including geographically dispersed members in programmatic activities.

Common fundraising across the partner institutions is encouraged, Subject all clinical protocols to the Cancer Center’s Protocol Review and Monitoring System (PRMS), Data and Safety Monitoring Institutional Plan (DSMP), and Clinical Protocol and Data Management (CPDM). A joint Institutional Review Board (IRB) for evaluation of all cancer research across the partner institutions is encouraged, but not required.

Have participation of the partner’s members in center’s disease- or modality-focused groups, PRMS, and DSMP. Grant the Cancer Center Director some influence in the management of the clinical cancer care program at the consortium partner to ensure that care is aligned with the research mission of the Center.

Have appropriate accrual to clinical trials proportionate to the patient population and clinical research capabilities of the consortium partner.

Have an appropriate cancer research administrative structure and staff to support cancer research, member engagement, and participation in Center activities, and that coordinates its efforts with the Center's Have a formal, written agreement (Memorandum of Understanding) in place to ensure the stability and integration of the consortium partnership.

The agreement should include: for resolution of differences at the highest levels of institutional leadership integrated planning and evaluation process that enables achievement of the Center’s research goals (e.g., identification of future recruitment needs, Shared Resources, Community Outreach and Engagement, and other activities) tangible institutional commitments to the Cancer Center from all consortium partners.

Such commitments should be appropriate to the nature of the consortium and may be demonstrated in a number of ways, including financial and in-kind contributions based on agreed upon formulas, housing and funding of Cancer Center cores, accrual to center-wide trials, active representation and engagement of members in Cancer Center Programs and committees, etc. Full eligibility for membership in formal Research Programs and leadership positions Reasonable access for all members to Shared Resources and clinical research materials including output from clinical trials, tissues, and HIPAA-compliant patient Director oversight of CCSG-supported Shared Resources, including those located delineation of the Center Director’s influence in the clinical operations at the A consortium partner without clinical activity must: Satisfy the requirements listed above, not including clinic-related activities, and hold at least $1.

0 million in direct cost NIH-funded research project grants that are classified as cancer research by NIH’s Research, Condition, and Disease Categorization (RCDC), held by a minimum of 5 PD/PIs.

These grants cannot be counted as part of the Center until the research partnership arrangement is approved by NCI, following acceptance of the arrangement by the NCI’s Cancer Centers Study Section (A) as part of their overall review of the DURATION: The initial budget period will be five years.

In order to enable more long-range planning and pursue high-risk research, Centers may be eligible for an additional two years, for a maximum award period of seven years. Eligibility for the additional years will be based on merit at peer review, sustained exceptional progress, stability, and longevity of the Cancer Center.

Additional years will be contingent upon an administrative review by NCI staff and approval of the National Information for award authorities and regulations. Section II. Award Information Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Application Types Allowed and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA. Optional: Accepting applications that either propose or do not propose clinical trial(s) help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Nonprofits without 501(c)(3) IRS Status (Other than Institutions City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system.

Please contact the NCI Office of Cancer Centers ( https://cancercenters. cancer. gov/ ) for assistance in determining the RCDC funding base.

For Renewal (Type 2) applications , an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions.

However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources).

Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: http://cancercenters. cancer. gov/documents/PeerReviewFundingOrganizations508C.

pdf New (Type 1) applications cannot request evaluation for comprehensiveness status. Non-domestic (non-U.S.) Entities (Foreign Institutions) are Non-domestic (non-U.S.) components of U.S. Organizations are not eligible Foreign components, as defined in the NIH Grants Policy Statement , are not allowed.

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted.

Registration can take 6 weeks or more, so applicants should begin the registration process as soon as Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number.

After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application. System for Award Management (SAM) Applicants must complete and maintain an active registration, which requires renewal at least annually .

The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.

must have an active DUNS number to register in eRA Commons. Organizations can register with the eRA Commons as they are working through their SAM or Grants. gov registration, but all registrations must be in place by time of submission.

eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application. must have an active DUNS number and SAM registration in order to complete the Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account.

PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 This FOA does not require cost sharing as defined in the NIH Grants Policy Statement . 3.

Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time.

This means that the NIH will A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101 ). to this FOA: Only one application per institution is allowed normally identified by having a unique DUNS number or NIH IPF number. Section IV.

Application and Submission Information The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the Multi-Project (M) Instructions (R&R) Application Guide , except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants. gov downloadable forms currently used with most NIH opportunities.

Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review. Strategy/Program Plan Page Limits Admin Core (use for Cancer Center Administration) Cancer Research Training and Education Coordination (CRTEC) Project (use for Research Programs) Community Outreach and Engagement (COE Clin.

Comp. Ctr.) Developmental Funds (Dev.

Funds) Shared Resource Management (Shared Res. Mgmt.) Leadership, Planning and Evaluation (Lead.

Plan. Eval.) Clinical Protocol and Data Management (CPDM Clin.

Comp. Ctr.) Protocol Review and Monitoring System (PRMS Clin.

Comp. Ctr.)] SR Component (use for Shared Resources) Additional page limits described in the SF424 Application Guide of Page Limits must be followed.

Instructions for the Submission of Multi-Component The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application. Revision applications must include an Overall component and the components that are affected by the revision. Therefore, the component requirements listed below may not apply to the revision application.

The application should consist of the following components: Core (use for Cancer Center Administration: minimum of 1; maximum Research Training and Education Coordination (CTREC): minimum of 1; maximum of (use for Research Programs: minimum of 1, no maximum) Outreach and Engagement (COE Clin. Comp. Ctr.)

: minimum of 1; maximum of 1 for Clinical and Comprehensive Cancer Centers, but not allowed for Basic Cancer Centers Funds (Dev. Funds): one optional Resource Management (Shared Res. Mgmt.)

: minimum of 1; maximum of 1 Planning and Evaluation (Lead. Plan. Eval.)

: minimum of 1; maximum of 1 Protocol and Data Management (CPDM Clin. Comp. Ctr): minimum of 1; maximum of 1 for Clinical and Comprehensive Cancer Centers, but not allowed for Basic Cancer Centers Review and Monitoring System (CPDM Clin.

Comp. Ctr): minimum of 1; maximum of 1 for Clinical and Comprehensive Cancer Centers, but not allowed for Basic Cancer Centers] Component (use for Shared Resources): minimum of 1, no maximum When preparing your application, use Component Type Overall . All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

SF424 (R&R) Cover (Overall) PHS 398 Cover Page Supplement (Overall) Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component. Project Information (Overall) Follow standard instructions. A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be